文献速递精神分裂症与精神病性障碍

阿米舒必利与奥氮平序贯氯氮平治疗首发精神分裂症的三阶段转换研究(OPTiMiSE)

Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study.
PubMed 文献 · Lancet Psychiatry · 2018-08-13

OPTiMiSE研究在14个欧洲国家和以色列的27个中心纳入446例首发精神分裂症谱系障碍患者,采用三阶段开放/双盲转换设计:先开放标签阿米舒必利4周,未缓解者双盲随机继续阿米舒必利或换用奥氮平6周,仍未缓解者开放标签氯氮平12周。结论支持简单序贯算法,并提示氯氮平应在单一抗精神病药失败后使用而非两种失败后。

要点

  • 首发精神分裂症患者中,阿米舒必利4周治疗可使56%达到症状缓解。
  • 氯氮平应在单一抗精神病药试验失败后使用,而非现行推荐的两药失败后。

核心结论

  • 对于多数早期精神分裂症患者,序贯使用阿米舒必利和氯氮平的简单治疗算法可实现症状缓解。
  • 换用奥氮平未改善结局,氯氮平应在单一抗精神病药治疗失败后使用,而非当前推荐的两个抗精神病药失败后。

研究设计与样本

  • 三阶段研究在14个欧洲国家和以色列的27个中心(综合医院和精神病专科门诊)进行。
  • 纳入18-40岁符合DSM-IV精神分裂症、精神分裂症样障碍或分裂情感性障碍的患者。
  • Phase 1为开放标签阿米舒必利(至800 mg/日)4周;未缓解者Phase 2双盲随机继续阿米舒必利或换用奥氮平(≤20 mg/日)6周;仍未缓解者Phase 3开放标签氯氮平(≤900 mg/日)12周。
  • 主要结局为各阶段最终访视时达到症状缓解的患者数,采用意向性治疗分析。

主要发现

  • 共招募481例签署知情同意,意向性治疗样本446例;371例(83%)完成开放标签阿米舒必利治疗,250例(56%)在Phase 1后达到缓解。
  • 10周治疗未缓解的40例中,28例(70%)开始氯氮平;18例(64%)完成12周治疗,5例(28%)达到缓解。
  • Phase 2严重不良事件无组间差异:奥氮平组1例因癫痫发作住院,阿米舒必利组1例因精神病性症状加重两次住院;整个试验报告2次严重自杀未遂。

关键数值与推荐

  • Phase 1缓解率:250/446(56%)。
  • Phase 3氯氮平缓解率:5/18(28%)完成治疗者中。

临床怎么用

  • 对首发精神分裂症患者可考虑先使用阿米舒必利治疗4周评估缓解情况。
  • 若阿米舒必利治疗未缓解,换用奥氮平并未显示优于继续阿米舒必利。
  • 氯氮平可在单一抗精神病药试验失败后考虑使用,而非等待两种药物失败。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: No established treatment algorithm exists for patients with schizophrenia. Whether switching antipsychotics or early use of clozapine improves outcome in (first-episode) schizophrenia is unknown. METHODS: This three-phase study was done in 27 centres, consisting of general hospitals and psychiatric specialty clinics, in 14 European countries and Israel. Patients aged 18-40 years who met criteria of the DSM-IV for schizophrenia, schizophreniform disorder, or schizoaffective disorder were treated for 4 weeks with up to 800 mg/day amisulpride orally in an open-label design (phase 1). Patients who did not meet symptomatic remission criteria at 4 weeks were randomly assigned to continue amisulpride or switch to olanzapine (≤20 mg/day) during a 6-week double-blind phase, with patients and staff masked to treatment allocation (phase 2). Randomisation was done online by a randomisation website; the application implemented stratification by site and sex, and applied the minimisation method for randomisation. Patients who were not in remission at 10 weeks were given clozapine (≤900 mg/day) for an additional 12 weeks in an open-label design (phase 3). The primary outcome was the number of patients who achieved symptomatic remission at the final visits of phases 1, 2, and 3, measured by intention-to-treat analysis. Data were analysed with a generalised linear mixed model, with a logistic link and binomial error distribution. This trial is registered with ClinicalTrials.gov, number NCT01248195, and closed to accrual. FINDINGS: Between May 26, 2011, and May 15, 2016, we recruited 481 participants who signed informed consent. Of the 446 patients in the intention-to-treat sample, 371 (83%) completed open-label amisulpride treatment, and 250 (56%) achieved remission after phase 1. 93 patients who were not in remission continued to the 6-week double-blind switching trial, with 72 (77%) patients completing the trial (39 on olanzapine and 33 on amisulpride); 15 (45%) patients on amisulpride versus 17 (44%) on olanzapine achieved remission (p=0·87). Of the 40 patients who were not in remission after 10 weeks of treatment, 28 (70%) started on clozapine; 18 (64%) patients completed the 12-week treatment, and five (28%) achieved remission. The number of serious adverse events did not differ between the treatment arms in phase 2: one patient on olanzapine was admitted to hospital because of an epileptic seizure, and one patient on amisulpride was admitted to hospital twice because of exacerbations of psychotic symptoms. Over the course of the trial, two serious suicide attempts were reported. INTERPRETATION: For most patients in the early stages of schizophrenia, symptomatic remission can be achieved using a simple treatment algorithm comprising the sequential administration of amisulpride and clozapine. Since switching to olanzapine did not improve outcome, clozapine should be used after patients fail a single antipsychotic trial-not until two antipsychotics have been tried, as is the current recommendation. FUNDING: European Commission Seventh Framework Program.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kahn RS, Winter van Rossum I, Leucht S, et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry. 2018. PMID: 30115598. doi:10.1016/S2215-0366(18)30252-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。